亚太药业(002370) - 2025 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders for 2025 is expected to be between 100 million and 120 million CNY, representing a growth of 192.06% compared to the previous year's profit of 34.24 million CNY [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 42 million to 60 million CNY, a decrease of 49.30% compared to the previous year's loss of 28.13 million CNY [2]. - Basic earnings per share are expected to be between 0.13 CNY and 0.16 CNY, compared to 0.05 CNY in the previous year [2]. - Operating revenue is forecasted to be between 350 million and 370 million CNY, down from 405.17 million CNY in the previous year [2]. Factors Influencing Profit - The increase in net profit is primarily due to the sale of 100% equity in a wholly-owned subsidiary, which added approximately 149 million CNY to the total profit for 2025 [5]. - Excluding non-recurring items, the decline in net profit is attributed to decreased sales revenue due to intensified market competition and centralized procurement [5]. - The company incurred additional financial expenses due to the redemption of convertible bonds at 115% of their face value, which matured on April 2, 2025 [5]. - A provision for impairment of 10.14 million CNY was made for the "R- ketoprofen sustained-release patch" project due to uncertainties in obtaining new drug certification [5]. Financial Reporting and Investor Advisory - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2025 annual report [6]. - Investors are advised to exercise caution and consider investment risks based on the preliminary financial estimates [6].